Deep Tech Fundraising: A $100M Case Study for Academics

The Frustrating Gap Between Discovery and Impact

For years, Sir Peter Donnelly, a professor at Oxford and one of the world’s leading geneticists, saw a recurring pattern. His field was producing incredible insights into the genetic underpinnings of human disease. Papers were published, grants were won, and inspiring talks were given about the potential to change patients' lives.

But the impact rarely left the lab. A massive, difficult gap existed between a "scientific breakthrough" and a real therapy helping someone on the front lines of healthcare. This wasn't for lack of good intentions; it was a systemic failure. The incentives in academia reward research, not the brutal, complex work of translation.

Donnelly decided to cross that gap himself. He, along with Gil McVean, Head of Oxford's Big Data Institute, and two others, founded Genomics PLC to do what academia couldn’t: turn genetic knowledge into tangible health outcomes.

The $100 Billion Problem: Why 90% of Drugs Fail

To attract venture capital, you need to attack a massive, expensive problem. Genomics PLC targeted one of the biggest bottlenecks in medicine: the astronomical failure rate of drug development.

Getting a single new drug to market can cost over $2 billion and take more than a decade. A huge portion of that cost is driven by clinical trials. Yet, an estimated 90% of all drugs that enter clinical trials fail . They prove to be unsafe or, more often, simply don’t work.

This is an efficiency crisis. Genomics' core insight was that genetics could act as a map to de-risk this process. By analyzing population-level genetic data, you can see which biological pathways are causally linked to a disease. If you develop a drug that targets one of these genetically-validated pathways, you dramatically increase its odds of success.

It’s the difference between randomly testing keys in a lock and having a schematic of the lock’s internal mechanism. This insight became the first pillar of their business: working with pharmaceutical companies to find better, genetically-validated drug targets.

The Vision: From Reactive Care to Genomic Prevention

The second pillar of the company is even more ambitious: restructuring healthcare itself. Today, most health systems operate on a "break-fix" model. We wait until people get sick, then spend enormous sums on treatment. This is financially unsustainable and leads to worse outcomes.

Donnelly and his team are pioneering "Genomic Prevention." The concept is simple but profound:

Identify Risk Early: Use a person's genetic data to calculate their "polygenic risk score" for common, serious diseases like heart disease, diabetes, and specific cancers. · Personalize Screening: Instead of blanket recommendations like "all women should get a mammogram at age 50," you can identify the small percentage of 35-year-olds who have the genetic risk of a 60-year-old and screen them much earlier. · Prevent, Don't Just Treat: For those at high risk, you can deploy preventative measures—from lifestyle changes to prophylactic therapies—before the disease ever manifests.

This shifts the entire paradigm from reactive to proactive. To prove it could work, Genomics PLC didn’t just publish papers. They started implementation studies with major health systems like the UK’s NHS and Stanford Health Care in the US, demonstrating a clear path to market adoption.

Lessons for Academic & Technical Founders

Raising nearly $100M for a company built on complex science is a rare feat. Donnelly’s journey from professor to founder holds critical lessons for anyone trying to commercialize a technical insight.

Mistake #1: Believing the discovery is the product.

In academia, the discovery is the end goal. In a startup, it’s the starting line. The "product" isn't the science; it's the entire apparatus for delivering that science as a service or therapy to a paying customer. This includes regulatory approval, marketing, sales, and customer support.

How to avoid it: From day one, obsess over the go-to-market plan. Who is the customer? What is their budget? How will you reach them? Who makes the purchasing decision? Your first critical hire after your technical co-founder should be someone who has experience answering these questions in your target industry.

Mistake #2: Hiring for academic prestige, not startup velocity.

A team of brilliant professors may be perfect for a research grant, but a startup needs builders, sellers, and operators. You need people who are comfortable with ambiguity, can execute at speed, and are motivated by commercial milestones, not just scientific curiosity.

How to avoid it: When hiring, screen for a "shipping" mindset. Ask candidates about a time they built something quickly with limited resources, not just a time they conducted a perfect, multi-year study. Your first 20 employees define your company’s DNA. Prioritize velocity and adaptability.

Mistake #3: Communicating like a scientist, not a storyteller.

Investors are not reviewing a grant application. They are buying into a future financial outcome. While the science must be sound, it must be framed in a compelling commercial narrative. Donnelly, a skilled debater from his youth, understood this. He didn’t just pitch the data; he pitched the vision of a more sustainable, preventative healthcare system.

How to avoid it: Structure your pitch deck as a story. Start with the massive, expensive problem. Introduce your solution as the unique key to unlocking this market. Show your team’s credibility. Demonstrate traction with early partners. A great pitch connects a technical solution to a human and financial need.

Building a Deep Tech Moat

Proprietary Data & Tools: Years of work building one of the most powerful platforms for linking genetic variation to disease. · World-Class Team: Anchored by founders who are global leaders in their field, which attracts top-tier talent. · Execution & Partnerships: Securing flagship partners like the NHS isn't just traction; it's a barrier to entry that competitors can't easily replicate.

How to Apply This This Week

Whether you're a professor in a lab or a founder with a technical idea, you can act on these insights now.

Map your "Valley of Death": Identify the biggest gap between your technical insight and a real-world product. Is it regulatory hurdles? A complex sales process? Manufacturing challenges? Get specific about the non-obvious, difficult steps. · Translate one insight into a commercial hypothesis: Take a finding from your work and frame it as a business case. "Because we discovered X, company Y will pay $Z to achieve outcome A." This simple exercise forces you to think like a customer. · Draft a "commercial co-founder" job description: Even if you aren't hiring, the act of writing the JD will clarify the skills you lack. What industry experience, sales background, or operational expertise would complement your technical strengths? · Re-read your pitch deck: Is it an investment opportunity or a science paper? Cut the jargon. Front-load the market size and the problem. Ensure every slide answers the investor's core question: "How does this make money and create a massive company?"